- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | INDP stock touches 52-week low at $1.02 amid market challenges | 1 | Investing.com | ||
| Di | INDP-Aktie erreicht 52-Wochen-Tief bei 1,02 US-Dollar | 1 | Investing.com Deutsch | ||
| 12.11. | Indaptus Therapeutics GAAP EPS of -$0.32 | 1 | Seeking Alpha | ||
| 12.11. | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology | 2 | GlobeNewswire (USA) | ||
| INDAPTUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.11. | Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting | 56 | GlobeNewswire (Europe) | NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer... ► Artikel lesen | |
| 22.10. | Indaptus Therapeutics geht Partnerschaft mit BeiGene für Krebsstudie ein | 12 | Investing.com Deutsch | ||
| 22.10. | Indaptus Therapeutics partners with BeiGene for cancer study | 1 | Investing.com | ||
| 22.10. | Indaptus Therapeutics signs clinical supply agreement with Beigene | 2 | Seeking Alpha | ||
| 22.10. | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10. | Indaptus Therapeutics maintains steady target with Buy rating | 2 | Investing.com | ||
| 25.09. | INDP stock touches 52-week low at $1.2 amid market challenges | 2 | Investing.com | ||
| 25.09. | INDP-Aktie erreicht 52-Wochen-Tief bei 1,2 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.09. | Indaptus Therapeutics files to sell 1.64M shares of common stock for holders | 2 | Seeking Alpha | ||
| 12.09. | Indaptus Therapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.09. | Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses | 72 | GlobeNewswire (Europe) | NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer... ► Artikel lesen | |
| 12.08. | Indaptus Therapeutics GAAP EPS of -$0.47 | 2 | Seeking Alpha | ||
| 12.08. | Indaptus Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 12.08. | Indaptus Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | Indaptus Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,000 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,350 | +0,79 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,755 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,580 | -3,72 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,935 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 17,070 | +5,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,260 | +0,16 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,295 | -0,35 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 6,955 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,600 | +1,10 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,000 | -2,86 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 25,140 | 0,00 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,750 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
INDAPTUS THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-1,87 %) liegt der Kurs bei 1,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INDAPTUS THERAPEUTICS INC finden Sie auf Wallstreet Online.
